Clinical Trial Search

Primary: Assessment of the Biosensors Ability to Track Phenoxymethylpenicillin Concentrations Compared to Observations Made by Microdialysis and Blood Sampling — -0.16 mg/L

Primary: Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants

Primary: Part 1, Cmax: Maximum Observed Plasma Concentration for TAK-931 Tablets in Reference to PIC — 251.45; 270.09 nanogram per milliliter (ng/mL)

Primary: Serum Concentration of Belimumab Following Intravenous Administration — 0.0; 26567.4; 63403.2; 64474.6 Nanograms per milliliter

Primary: Maximum Plasma Concentration (Cmax) for Griseofulvin — 2229; 2877; 1927 Nanograms per milliliter

Primary: Percentage of Participants With Adverse Events (AEs) and AEs of Special Interest — 75.0; 87.5; 37.5; 75.0 Percentage of Participants

Primary: Number of Participants With Treatment Emergent Adverse Events — 17; 15; 8 Participants

Primary: Area Under the Serum Concentration-time Curve From Dosing to Infinity (AUC) — 41.3; 62.9; 83.1 h*ng/mL

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability] — 2; 0; 0; 3 Participants

Primary: Number of Participants With Dose-Limiting Toxicities — 0; 0 Participants

Primary: Number of Participants With Adverse Events (AEs) - Carbiralizumab Monotherapy — 3; 4 Number of participants

Primary: Number of Participants With Adverse Events and/or Dose Limiting Toxicities as a Measure of Safety and Tolerability of Dose of PD-1 Knockout T Cells Using Common…

Primary: Number of Subjects With Serious and Non-serious Adverse Events. — 0; 0; 0 Participants

Primary: Maximum Observed Plasma Concentration (Cmax) for PF-04965842 — 1174; 1626; 1164 nanogram per milliliter (ng/mL)

Primary: Pharmacokinetic (PK) Parameter: AUClast of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate) — 160.6…